Adverse analytical findings (AAFs) reported for glucocorticoids 2010–2018
| Year | Number of AAF | % of total AAF | Substance | Occurrences | % within drug class |
| 2010 | 234 | 4 | Budesonide* | 111 | 47.4 |
| Prednisolone+prednisone | 39 | 16.7 | |||
| Betamethasone | 27 | 11.5 | |||
| Prednisolone | 16 | 6.8 | |||
| Prednisone | 9 | 3.8 | |||
| Dexamethasone | 8 | 3.4 | |||
| Methylprednisolone | 7 | 3.0 | |||
| Triamcinolone acetonide | 7 | 3.0 | |||
| Triamcinolone | 6 | 2.6 | |||
| Deflazacort | 3 | 1.3 | |||
| Fluticasone propionate | 1 | 0.4 | |||
| 2011 | 274 | 5 | Budesonide* | 113 | 41.2 |
| Prednisolone+prednisone | 40 | 14.6 | |||
| Betamethasone | 25 | 9.1 | |||
| Dexamethasone | 21 | 7.7 | |||
| Prednisolone | 19 | 6.9 | |||
| Prednisone | 19 | 6.9 | |||
| Methylprednisolone | 16 | 5.8 | |||
| Triamcinolone acetonide | 16 | 5.8 | |||
| Triamcinolone | 2 | 0.7 | |||
| Fluticasone propionate | 2 | 0.7 | |||
| Deflazacort | 1 | 0.4 | |||
| 2012 | 365 | 8 | Budesonide* | 157 | 43.0 |
| Prednisolone | 67 | 18.4 | |||
| Prednisone | 60 | 16.4 | |||
| Betamethasone | 30 | 8.2 | |||
| Dexamethasone | 18 | 4.9 | |||
| Triamcinolone acetonide | 16 | 4.4 | |||
| Methylprednisolone | 15 | 4.1 | |||
| Triamcinolone | 1 | 0.3 | |||
| Fluticasone propionate | 1 | 0.3 | |||
| 2013 | 330 | 6 | Budesonide* | 135 | 40.9 |
| Prednisolone | 58 | 17.6 | |||
| Prednisone | 55 | 16.7 | |||
| Betamethasone | 35 | 10.6 | |||
| Dexamethasone | 18 | 5.5 | |||
| Methylprednisolone | 14 | 4.2 | |||
| Triamcinolone acetonide | 12 | 3.6 | |||
| Fluticasone propionate | 2 | 0.6 | |||
| Triamcinolone | 1 | 0.3 | |||
| 2014 | 252 | 8 | Budesonide* | 74 | 29 |
| Prednisolone | 56 | 22 | |||
| Prednisone | 44 | 17 | |||
| Betamethasone | 34 | 13 | |||
| Triamcinolone acetonide | 16 | 6 | |||
| Methylprednisolone | 14 | 6 | |||
| Dexamethasone | 12 | 5 | |||
| Deflazacort | 1 | 0.4 | |||
| Triamcinolone | 1 | 0.4 | |||
| 2015 | 215 | 6 | Prednisolone | 60 | 28 |
| Prednisone | 52 | 24 | |||
| Betamethasone | 31 | 14 | |||
| Dexamethasone | 19 | 9 | |||
| Methylprednisolone | 19 | 9 | |||
| Triamcinolone acetonide | 17 | 8 | |||
| Budesonide* | 7 | 3 | |||
| Deflazacort | 4 | 2 | |||
| Fluticasone propionate | 3 | 1 | |||
| Fluticasone | 2 | 1 | |||
| Triamcinolone | 1 | 0.5 | |||
| 2016 | 184 | 4 | Prednisolone | 51 | 28 |
| Prednisone | 48 | 26 | |||
| Betamethasone | 29 | 16 | |||
| Triamcinolone acetonide | 18 | 10 | |||
| Dexamethasone | 13 | 7 | |||
| Methylprednisolone | 11 | 6 | |||
| Fluticasone propionate | 9 | 5 | |||
| Deflazacort | 2 | 1 | |||
| triamcinolone | 2 | 1 | |||
| Budesonide* | 1 | 0.5 | |||
| 2017 | 224 | 5 | Prednisolone | 70 | 31 |
| Prednisone | 56 | 25 | |||
| Triamcinolone acetonide | 31 | 14 | |||
| Betamethasone | 23 | 10 | |||
| Dexamethasone | 20 | 9 | |||
| Methylprednisolone | 13 | 6 | |||
| Fluticasone propionate | 4 | 2 | |||
| Deflazacort | 3 | 1 | |||
| Budesonide* | 2 | 1 | |||
| Triamcinolone | 1 | 0 | |||
| 2018 | 284 | 7 | Prednisolone | 77 | 27 |
| Triamcinolone acetonide | 72 | 25 | |||
| Prednisone | 70 | 25 | |||
| Betamethasone | 34 | 12 | |||
| Dexamethasone | 15 | 5 | |||
| Methylprednisolone | 8 | 3 | |||
| Budesonide* | 5 | 2 |
MRL revised to lower values are highlighted in dark grey; MRL revised to higher values are highlighted in light grey.
*Note that the change in prevalence is due to change in target analyte from budesonide to N6β-hydroxy-budesonide in 2014.